Valuation : MacroGenics, Inc.

Market Cap 263M 227M 213M 194M 366M 25.14B 367M 2.52B 984M 12.69B 988M 966M 42.09B P/E 2026 *
-2.66x
P/E 2027 * -2.7x
Enterprise Value 263M 227M 213M 194M 366M 25.14B 367M 2.52B 984M 12.69B 988M 966M 42.09B EV / Sales 2026 *
2.3x
EV / Sales 2027 * 2.68x
Free-Float
96.52%
Yield 2026 *
-
Yield 2027 * -
1 day+1.23%
1 week+0.73%
Current month+11.92%
1 month+12.53%
3 months-0.72%
6 months+107.54%
Current year+156.52%
1 week 3.96
Extreme 3.965
4.2
1 month 3.61
Extreme 3.61
4.31
Current year 1.58
Extreme 1.58
5.08
1 year 1.29
Extreme 1.29
5.08
3 years 0.99
Extreme 0.98965
21.88
5 years 0.99
Extreme 0.98965
28.09
10 years 0.99
Extreme 0.98965
36.48
Manager TitleAgeSince
Chief Executive Officer 53 2025-08-12
Director of Finance/CFO 59 2008-04-30
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 73 2001-08-31
Director/Board Member 53 2025-08-12
Director/Board Member 62 2004-09-30
Date Insider Type Main position Quantity % Market Cap.
8/19/26 Sell

General Counsel

-31,105 0.0489%
8/17/26 Fiscal year

Chief Technology Officer

80,000 0.1259%
5/19/26 Free

Director

25,750 0.0405%
Change 5-day change 1-year change 3-year change Capi.($)
+1.23%+0.73%+133.33%-16.90% 263M
-1.59%-3.35%+52.37%+93.70% 69.54B
-1.34%-0.75%+48.21%+91.86% 64.97B
+0.30%-0.69%+52.56%+10.23% 26.51B
-2.35%-5.75%-12.90%+448.54% 25.89B
-8.37%-12.43%+2.08%-16.71% 25.64B
-0.96%+10.36%+283.06%+436.50% 20.22B
-0.51%+0.23%+35.77%-18.70% 19.98B
-1.91%-4.37%+13.28%+535.19% 15.69B
-1.47%+0.68%+45.51%+143.08% 13.49B
Average -1.70%-1.71%+65.33%+170.68% 28.22B
Weighted average by Cap. -1.93%-1.50%+53.80%+151.35%

Financials

2026 *2027 *
Net sales 115M 98.73M 92.57M 84.5M 159M 10.95B 160M 1.1B 429M 5.53B 430M 421M 18.33B 98.35M 84.75M 79.46M 72.53M 137M 9.4B 137M 943M 368M 4.74B 369M 361M 15.73B
Net income -88.02M -75.85M -71.11M -64.92M -122M -8.41B -123M -844M -329M -4.25B -330M -323M -14.08B -128M -110M -103M -94.13M -177M -12.2B -178M -1.22B -477M -6.16B -479M -469M -20.42B
Net Debt - -
Logo MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates from its proprietary suite of antibody technology platforms. It is developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which are referred to as DART and TRIDENT molecules). It has multiple proprietary product candidates. These include three clinical-stage ADCs incorporating a novel topoisomerase I inhibitor (TOP1i)-based linker-payload: MGC026, which targets B7-H3; MGC028, which targets ADAM9, and MGC030, which is directed against an undisclosed target. It is also developing lorigerlimab, a clinical-stage bispecific DART molecule targeting the immune checkpoint receptors PD-1 and CTLA-4. In addition, it is also developing multiple preclinical-stage ADC and next-generation T-cell engager programs.
Employees
293
Date Price Change Volume
26-08-28 $4.130 +1.23% 541,659
26-08-27 $4.080 +0.99% 319,942
26-08-26 $4.040 -3.12% 263,034
26-08-25 $4.170 +3.73% 363,137
26-08-24 $4.020 -1.95% 432,774
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
4.130USD
Average target price
7.250USD
Spread / Average Target
+75.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MGNX Stock